Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Raw Materials (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Raw Materials for 3 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 134.88% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2025, up 134.88% year-over-year, with the annual reading at $4.1 million for FY2025, 134.88% up from the prior year.
  • Raw Materials for Q4 2025 was $4.1 million at Phathom Pharmaceuticals, up from $1.0 million in the prior quarter.
  • The five-year high for Raw Materials was $4.1 million in Q4 2025, with the low at $111000.0 in Q2 2023.
  • Average Raw Materials over 3 years is $1.3 million, with a median of $1.0 million recorded in 2025.
  • The sharpest move saw Raw Materials soared 1717.12% in 2024, then plummeted 50.02% in 2025.
  • Over 3 years, Raw Materials stood at $561000.0 in 2023, then skyrocketed by 208.2% to $1.7 million in 2024, then surged by 134.88% to $4.1 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $4.1 million, $1.0 million, and $991000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.